-Director, Millennium Pharmaceuticals, Inc.
-Director, Cardiovascular Research Institute (VRI)
-Professor of Medicine and Cellular and Molecular Pharmacology, University of California at San Francisco

Research:
Dr. Coughlin's cardiovascular research discovered how thrombin, an enzyme that causes blood to clot, works on the cellular level. In the process, he identified a new family of receptors that are broadly involved in a number of biological processes and have important implications for the development of novel treatments for diseases and pathologic events in which thrombosis plays an important role, including heart attacks and many strokes. His discoveries led to a greater understanding of platelets and clot formation.

Career Highlights:
Dr. Coughlin received his BS and MS degrees in 1976, and his PhD in 1981 from the Massachusetts Institute of Technology, and an MD from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology in 1982. He joined the Cardiovascular Research Institute at the University of California, San Francisco in 1984 as a postdoctoral fellow and joined the faculty in 1986. He was named professor of medicine in 1996 and was appointed professor of cellular and molecular pharmacology, as well as director of the Cardiovascular Research Institute in 1997.

Dr. Coughlin serves as a director of Millennium Pharmaceuticals and of Gorilla Genomics.

Dr. Coughlin is the recipient of numerous honors and awards. In 2004 he won the Bristol Myers Squibb Cardiovascular Research Award and he was elected to the National Academy of Science. He is also a member of the editorial boards of Trends in Cardiovascular Medicine, Molecular Medicine and Journal of Clinical Investigation.